1.Challenges and common sense of PS≥2 patients with non-small cell lung cancer
Cancer Research and Clinic 2000;0(01):-
The performance status(PS)≥2 patients with non-small cell lung cancer(NSCLC) are short of effective management.The phase Ⅱ/Ⅲ clinical trails of target therapy of anti EFGR of VEGFR have already got promise results.This article expatiates the actuality and development of the chemotherapy and novel target therapy for the PS≥2 patients with NSCLC.
2.Comparative study of periocular injection and subconjunctival injection in treatment of iridocyclitis
Yuhua TANG ; Yiru XU ; Xiangyun SHU ; Sendi YE ; Xiaoying ZHENG
Chinese Journal of Practical Nursing 2010;26(12):43-44
Objective To discuss different effect of periocular injection and subconjunctival injection in treatment of iridocyclitis. Methods Eighty people with iridocyclitis were divided into group A and group B according to their admission order. Group A adopted periocular injection and group B was given subconjunctival injection. The incidence of complication was compared between the two groups. Results Significant difference existed in complications and related factors between two groups after treatment, periocular injection proved to be superior to subconjunctival injection. Conclusions Periocular injection is a desirable treatment method for iridocyclitis. It is easy to operate, safe, rapid and with less pain, so it is worthy of clinical application.
3.Docetaxel for 15 patients with paclitaxel-resistant advanced non-small cell lung cancer
Yifei ZHANG ; Yunhua XU ; Xiangyun YE ; Ziming LI ; Linping GU ; Shun LU
Cancer Research and Clinic 2009;21(7):458-460
Objective To determine the efficacy and toxicity of docetaxel in patients with paclitaxel-resistant advanced non-small cell lung cancer (NSCLC). Methods The clinical data from 15 patients with NSCLC who were admitted in the Shanghai Chest Hospital from January 2005 to May 2008 were retrospectively analyzed. The effects and toxicities of the second-line treatment were assessed. The progression-free survival time(PFS) and overall survival time(OS) were analyzed. Results The disease control rate was 66.7 %, with a progression-free survival time of 6 months, and a overall survival time of 17.3 months. The 1-year survival rate was 63.3 %. The toxic effects were as expected. Conclusion The doeetaxel-based agent is active in patients with paelitaxel-resistant advanced NSCLC.
4. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins
Fengling WANG ; Xiangyun MENG ; Rongjuan CAO ; Zhengmin HE ; Xi YE ; Qi LI ; Zhengxu CHEN ; Cong WANG
Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(1):40-48
AIM: To investigate the polymorphism distribution of lipid and drug metabolism-related genes of SLCO1B1 and ApoE in patients with cardiovascular disease of Han nationality in Anhui province, and to evaluate the benefit-risk ratio of individual use of statins. METHODS: PCR fluorescence probe technique was used to detect the genetic polymorphism of rs2306283 (388A>G) and rs4149056 (521T>C) of SLCO1B1 as well as rs429358 (388 T>C) and rs7412 (526C>T) of ApoE in 736 individuals diagnosed with cardiovascular diseases in the inpatient department of the Second People's Hospital of Hefei from January 2019 to August 2020 were included. The distribution characteristics of SLCO1B1 and ApoE genotypes were analyzed according to the gender of the subjects, and the results of genetic polymorphism were compared with the data of cardiovascular disease patients in other areas of China. RESULTS: Six genotypes of SLCO1B1 had been detected. They were *1a/*1a (6.11%), *1a/*1b (29.08%), *1b/*1b (44.57%), *1a/*15 (4.08%), *1b/*15 (15.49%) and *15/*15 (0.68%), while *1a/*5, *5/*5 and *5/*15 had not been detected. Six genotypes of ApoE had been detected. They were E2/E2 (0.41%), E2/E3 (11.96%), E2/E4 (1.09%), E3/E3 (67.66%), E3/E4 (17.93%) and E4/E4 (0.95%). The frequency distribution of genetic polymorphism of these two genes satisfied the Hardy-Weinberg genetic equilibrium, which was representative of the population. In this study, the proportion of people with SLCO1B1 normal myopathy risk was the highest, accounting for 79.76%; SLCO1B1 had a lower proportion of people with moderate myopathy risk and high myopathy risk were 19.57% and 0.68%, respectively. The reduced risk, normal risk and increased risk phenotypes of ApoE were respectively 12.37%, 68.75% and 18.88%. There was no statistically significant difference in SLCO1B1 and ApoE genotypes beween gender. Compared with patients with cardiovascular disease in Southern China area, the distribution of ApoE genetic polymorphism was significantly different in Anhui. CONCLUSION: The SLCO1B1 and ApoE genetic polymorphism of 736 patients with cardiovascular diseases in Anhui were mainly normal myopathy risk types with higher dose tolerance of statins as well as popular genotypes that were sensitive to statins, and the application of statins has a lower risk of myopathy and a good effect on lipid reduction. The polymorphism of the two genes was not affected by gender, but the distribution phenotypes of ApoE might be different in regional characteristics. The detection of SLCO1B1 and ApoE genetic polymorphism is significant for evaluation of benefit-risk ratios, thereby guiding statins clinical treatment.
5.Improvement and Anti-inflammation Mechanism of Shenfu Injection on Lung Tissue in Endotoxin Shock Model Rats
Xia LIU ; Fei AI ; Chunwei CHU ; Xiangyun CHEN ; Junfeng GUO ; Yi YANG ; Liyan MEI ; Jifei MIAO ; Quan WEN ; Sen YE ; Hui LI
China Pharmacy 2019;30(11):1492-1497
OBJECTIVE: To study the improvement and anti-inflammation mechanism of Shenfu injection on lung tissue of endotoxin shock model rats. METHODS: Totally 48 rats were randomized into control group,model group,dexamethasone group (positive control,1 mg/kg) and Shenfu injection low-dose,medium-dose and high-dose groups (5,10,15 mL/kg),with 8 rats in each group. Except for normal group, other groups were given intraperitoneal injection of lipopolysaccharide (LPS) to induce endotoxin shock model. After modeling, each group was given relevant medicine once intraperitoneally. 24 h after medication, HE staining was used to observe pathological changes of lung tissue in rats and pathological scoring was conducted. RT-PCR was used to determine mRNA levels of P65 and P50 proteins related to NF-κB signaling pathway. Western blot assay was used to determine the expression levels of P65 and P50 proteins in lung tissue, and the expression levels of P65 protein in nucleus and cytoplasm of lung tissue were also determined. The level of TNF-α in plasma in rats were determined by ELISA. RESULTS: Compared with control group, alveolar septum became thicker, obvious vascular engorgement was found, and a large number of neutrophils infiltrated the interstitium in model group. Histopathological score, mRNA and protein expression levels of P65 and P50 in lung tissues were increased significantly (P<0.01 or P<0.001); the protein expression of levels P65 in nucleus and cytoplasm and level of TNF-α in plasma were increased significantly (P<0.001). Compared with model group, alveolar structure of rats in dexamethasone group and Shenfu injection medium-dose and high-dose groups was complete, no obvious bleeding was observed, and the degree of inflammatory cell infiltration was improved significantly. Histopathological score, mRNA and protein expression levels of P65 and P50 in lung tissue and level of TNF-α in plasma were decreased significantly (P<0.05 or P<0.01 or P<0.001). The protein expression level of P65 in nucleus and cytoplasm of lung tissue were decreased significantly in dexamethasone group and Shenfu injection low-dose and medium-dose groups were decreased significantly (P<0.05 or P<0.01 or P<0.001). CONCLUSIONS: Shenfu injection can decrease mRNA and protein expression levels of P65 and P50 in lung tissue, level of TNF-α in plasma, and protect lung tissue of endotoxin shock rats.
6.Intervention Effect of Shenfu Injection on the Nuclear Translocation of HMGB 1 in LPS-induced RAW 264.7 Cells
Fei AI ; Xia LIU ; Hui LI ; Chunwei CHU ; Xiangyun CHEN ; Junfeng GUO ; Yi YANG ; Liyan MEI ; Jifei MIAO ; Quan WEN ; Sen YE
China Pharmacy 2020;31(21):2585-2591
OBJECTIVE:To investigate the intervention effect of Shenfu i njection(SFI)on the nuclear translocation of high mobility group box 1(HMGB1) in lipopolysaccharide (LPS)-induced RAW 264.7 cells. METHODS : Using LPS-induced RAW264.7 cells as objects ,the histone deacetylase inhibitor RGFP 966 as positive control ,CCK-8 assay was used to screen drug dosage,and the effects of low ,medium and high doses (3,6,12 μL/mL)of SFI on HMGB 1 nuclear translocation in RAW 264.7 cells were observed by immunofluorescence method ;mRNA expression of HMGB 1 in RAW 264.7 cells were detected by real time fluorescent PCR. Western blotting assay was used to determine protein expression of HMGB 1 and Toll-like receptor 4(TLR4);the expression of HMGB 1 were compared between nucleus and cytoplasm. The levels of HMGB 1,IL-1β and TNF-α in supernatant of cells were detected by ELISA. RESULTS :In blank control group ,HMGB1 was mainly located in the nucleus ;after LPS induction, HMGB1 migrated from nucleus to cytoplasm. Compared with blank control group , mRNA and protein (No.81760738) expression of HMGB 1, protein expression of TLR 4 in RAW264.7 cells as well as the levels of HMGB 1,IL-1β and TNF-α in supernatant of cells were increased significantly in LPS group (P<0.01). The protein expression of HMGB 1 was decreased significantly in nucleus while was in creased significantly in cytoplasm (P<0.01). After SFI treatment ,the nuclear translocation and secretion of HMGB 1 were inhibited in different degrees ;compared with LPS group ,mRNA and protein expression of HMGB 1 in administration groups ,protein expression of TLR 4 in RAW 264.7 cells of positive control group ,SFI medium- and high-dose groups as well as the levels of HMGB 1,IL-1β and TNF-α in supernatant of cells in administration groups were decreased significantly (P<0.01). In positive control group ,SFI medium- and high-dose groups ,the protein expressions of HMGB1 in nucleus were increased significantly ,while protein expressions of HMGB 1 in cytoplasm were decreased significantly (P<0.01). CONCLUSIONS :SFI may inhibit the nuclear translocation and secretion of HMGB 1 in RAW 264.7 cells,thus avoiding the activation of inflammatory pathways and the production of inflammatory factors ,so as to reduce the inflammatory response induced by LPS.